Toggle Nav

LY2835219 free base

In stock
Catalog No.
CDK inhibitor
Grouped product items
SizePriceStock Qty
In stock
In stock
In stock

Tel: +1-832-696-8203


Worldwide Distributors

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Physical Appearance

A solid

Chemical Properties

StorageStore at -20°C
Cas No.1231929-97-7
SynonymsCDK4/6 dual inhibitor;LY 2835219 (free base);LY-2835219 (free base)
Solubility≥4.83 mg/mL in DMSO with ultrasonic and warming, <2.52 mg/mL in H2O, ≥6.34 mg/mL in EtOH with gentle warming
Chemical NameN-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
SDFDownload SDF
Canonical SMILESCCN1CCN(CC2=CN=C(NC3=NC=C(F)C(C4=CC5=C(N=C(C)N5C(C)C)C(F)=C4)=N3)C=C2)CC1
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Quality Control

Chemical structure

LY2835219 free base